Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study

References

• Passweg JR, Baldomero H, Bader P, et al. European society for Blood and Marrow Transplantation (EBMT). Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European society for blood and marrow transplant activity survey report. Bone Marrow Transplant. 2018.
   Google Scholar
• Pusic I, Jiang S, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–1056.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Varmavuo V, Juutilainen A, et al. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol. 2012;91:1073–1079.
   PubMed Web of Science ®Google Scholar
• Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin lymphoma, Hodgkin disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331–338.
   PubMed Web of Science ®Google Scholar
• DiPersio J, Stadtmauer E, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• Sahin U, Demirer T. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. J Clin Apher. 2017.
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588–596.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91:3148–3155.
   PubMed Web of Science ®Google Scholar
• Klaus J, Herrmann D, Breitkreutz I, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation . Eur J Haematol. 2007;78:21–28.
   PubMed Web of Science ®Google Scholar
• Weaver C, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969.
   PubMed Web of Science ®Google Scholar
• Toor A, Ayers J, Strupeck J, et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol. 2004;124:769–776.
   PubMed Web of Science ®Google Scholar
• O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37:731–737.
   PubMed Web of Science ®Google Scholar
• Wahlin A, Eriksson M, Hultdin M. Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haematol. 2004;73:263–268.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion. 2012;52:1785–1791.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol. 2012;89:128–135.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Silvennoinen R, et al. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion. 2013;53:1024–1032.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Blood graft cellular composition and posttransplant recovery in non-Hodgkin lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion. 2015;55:2358–2368.
   PubMed Web of Science ®Google Scholar
• Hiwase D, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:116–124.
   PubMed Web of Science ®Google Scholar
• Lee S, Yahng S, Cho B, et al. Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma. Cytotherapy. 2012;14:505–512.
   PubMed Web of Science ®Google Scholar
• Porrata L, Gertz M, Geyer S, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2004;18:1085–1092.
   PubMed Web of Science ®Google Scholar
• Valtola J, Silvennoinen R, Ropponen A, et al. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion. 2016;56:1394–1401.
   PubMed Web of Science ®Google Scholar
• Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher. 2017;32:224–234.
   PubMed Web of Science ®Google Scholar
• Worel N, Frank N, Frech C, et al. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017;57:2206–2215.
   PubMed Web of Science ®Google Scholar
• Silvennoinen R, Anttila P, Säily M, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide + G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant. 2016;51:372–376.
   PubMed Web of Science ®Google Scholar
• Gratama J, Kraan J, Keeney M, et al. Validation of the single-platform ISHAGE method for CD34+ hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy. 2003;5:55–65.
   PubMed Web of Science ®Google Scholar
• Alexander E, Towery J, Miller A, et al. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion. 2011;51:1995–2000.
   PubMed Web of Science ®Google Scholar
• Micallef I, Stiff P, Stadtmauer E, et al. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin lymphoma or multiple myeloma. Am J Hematol. 2013;88:1017–1023.
   PubMed Web of Science ®Google Scholar
• Russell N, Douglas K, Ho A, et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica. 2013;98:172–178.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Uberti J, Devine S, et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013;48:777–781.
   PubMed Web of Science ®Google Scholar
• Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 2011;51:968–975.
   PubMed Web of Science ®Google Scholar
• Moreb J, Salmasinia D, Hsu J, et al. Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients. Adv Hematol. 2011;2011:1–8.
   Google Scholar
• Holtan S, Porrata L, Micallef I, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymph Myeloma. 2007;7:315–318.
   PubMedGoogle Scholar
• Pérez-Andres M, Almeida J, Martin-Ayuso M, et al. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer. 2006;106:1296–1305.
   PubMed Web of Science ®Google Scholar
• Debnath B, Xu S, Grande F, et al. Small molecule inhibitors of CXCR4. Theranostics. 2013;3:47–75.
   PubMed Web of Science ®Google Scholar
• Tricot G, Cottler-Fox M, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. 2010;45:63–68.
   PubMed Web of Science ®Google Scholar
• Porrata L, Gertz M, Inwards D, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Moreb J, Byrne M, Shugarman I, et al. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. J Clin Apher. 2018;33:29–37.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–2962.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff PJ, Nademanee AP, et al. Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: long-term follow-up report. Biol Blood Marrow Transplant. 2018;24:1187–1195.
   PubMed Web of Science ®Google Scholar
• Garfall A, Dougherty A, Vogl D, et al. Association between mobilization regimen and PFS after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2014;49:1439–1441.
   PubMed Web of Science ®Google Scholar
• Morris C, Sureda A, van BA, et al. The EMA-directed plerixafor safety survey: the EBMT CALM study. Bone Marrow Transplant. 2011;46:S32.
   Web of Science ®Google Scholar